Stock Alert: Arcturus Shares Up 15% In Premarket

(RTTNews) - Shares of Arcturus Therapeutics Holdings Inc. (ARCT) are rising above 15% in pre-market today, after the company reported positive immunogenicity data from its preclinical study for its COVID-19 Vaccine. These data for LUNAR-COV19 were measured by Duke-NUS Medical School in Singapore.

Pad Chivukula, Chief Scientific Officer of Arcturus Therapeutics, said, "These data show that Arcturus' STARR mRNA is superior to conventional mRNA at all equivalent doses and timepoints. Self-replicating mRNA significantly increases spike protein expression, yielding many-fold higher seroconversion rates. The results at the 2 µg dose suggest LUNAR-COV19 has the potential to immunize millions more people."

The stock has been trading between $5.70 and $23.64 in the past one year, and closed Friday's trade at $22.57, up $2.06 or 10.04%. ARCT is currently trading at $25.99, up $3.42 or 15.15% in the pre-market trading session.